Pharmaceutical Pipeline
Yale is committed to advancing healthcare through groundbreaking technologies and discoveries. Explore a diverse array of pioneering projects that span the entire drug development process, from early-stage research to clinical trials. With a focus on addressing critical medical challenges, Yale's Pharmaceutical Pipeline showcases the collective expertise and dedication of our researchers who are aiming to bring tangible solutions to market for patients worldwide.
Device Diagnostic
Preclinical
Troxatyl
- Beijing HebaBiz
RIG-101
- RIGImmune
- Oncology
Mucosal covid vaccine
- Xanadu Bio
EGFR-Her2 vaccine
- Therajan
INZ-701 - Calciphylaxis
Our lead candidate, INZ-701, is in clinical development for the potential treatment of ENPP1 Deficiency and ABCC6 Deficiency, which are driven by low levels of inorganic pyrophosphate (PPi) andadenosine. Currently, there are no therapeutic options for patients suffering from ENPP1 Deficiency and ABCC6 Deficiency – two rare disorders. We are pioneering the development of effective therapies for these patients and their families.
BHV-1310
Myasthenia Gravis
RATIONALE:
Molecular Degraders of Extracellular Proteins (“MoDE™”) are bispecific molecules that target pathologic circulating proteins and direct them to the liver (or other organ systems) for degradation by the endosomal/lysosomal pathway. Hepatic asialoglycoprotein receptor (ASGPR) ligand degraders able to recognize all potentially pathogenic isoforms of IgG represent a novel, competitive platform with a differentiated profile relative to FcRN inhibitors. Specifically, high circulating levels of antibodies (monoclonal or polyclonal gammopathy) drive conditions such as myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgaris, and many other diseases. It is hypothesized that rapid and sustained lowering of pathogenic antibody titers in blood will significantly reduce disease symptoms. BHV-1310 demonstrates 90% IgG depletion with a single dose. Therapeutic pan-IgG depletion using Biohaven’s proprietary MoDE™ platform technology is expected to have significant potential benefit for multiple diseases.
- Inflammatory
BHV-1600
INDICATION: Dilated Cardiomyopathy
RATIONALE:
Cardiac beta-1 adrenergic receptors (β1-AR), when activated, increase heart rate, contractility, and cardiac output. There is a high prevalence of agonistic autoantibodies that activate cardiac β1-AR in multiple cardiomyopathies, which lead to dilation of the heart and heart failure. The presence of β1-AR autoantibodies correlates with a poor prognosis, and removing or neutralizing β1-AR autoantibodies has shown potential therapeutic benefits. BHV-1600 is a bifunctional MoDE designed to selectively degrade pathogenic β1-AR autoantibodies and should augment the limited efficacy of beta-blockers, providing a novel approach to treating multiple cardiomyopathies.
- Antibody
- Cardiovascular
BHV-1400
IgA nephropathy (“IgAN”) is the most common primary glomerulonephritis that can progress to renal failure and is characterized by immunoglobulin deposits in the renal mesangium comprised exclusively of the IgA1 subclass. Currently, no IgAN-specific therapies are available. Patients are managed with the aim of controlling blood pressure and maintaining renal function.
- Discovery Platform
- Inflammatory
- Rare Disease
- Therapeutics
EGFR-Her2 vaccine
- Therajan
Canine cancer
Troxatyl
- Beijing Heba Biz
Cancer
VesiculoVax™
RSV, EquineEncephalitis
GFB-204
Cancer
Triplex Gene Editing
SickleCell, CysticFibrosis
Nanoparticle vaccine
Peanut Allergy
Chikungunya–VesiculoVax™
Chikungunya
PBS Vax™-VSV Vaccine
HSV, HBV, HCV, HPV, RSV
RX-04
Antibacterial
Lassa–VesiculoVax™
Lassa
Phase I
PTX-100
- Prescient
BHV-1300
Molecular Degraders of Extracellular Proteins (“MoDE™”) are bispecific molecules that target pathologic circulating proteins and direct them to the liver (or other organ systems) for degradation by the endosomal/lysosomal pathway---a novel, competitive platform with a differentiated profile relative to FcRN inhibitors. Specifically, high circulating levels of antibodies (monoclonal or polyclonal gammopathy) drive conditions such as myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgaris, and many other diseases.
- Discovery Platform
- Inflammatory
- Therapeutics
HLD-0915
- Halda Therapeutics
BCSZ110
- Dynamicure
PTX-100
- Prescient
Cancer
BIS-001ER
Undisclosed
NC410
Oncology
AXER-204
SpinalCord/Stroke
Phase II
ARV-766-mCRPC
- Arvinas
ARV-110
- Arvinas
INZ-701 - ABCC6 Deficiency
Our lead candidate, INZ-701, is in clinical development for the potential treatment of ENPP1 Deficiency and ABCC6 Deficiency, which are driven by low levels of inorganic pyrophosphate (PPi) andadenosine. Currently, there are no therapeutic options for patients suffering from ENPP1 Deficiency and ABCC6 Deficiency – two rare disorders. We are pioneering the development of effective therapies for these patients and their families.
ARV-110
- Arvinas
Prostate Cancer
- Oncology
ARV-471
- Arvinas
Breast Cancer
- Oncology
Phase III
ARV-471
- Arvinas
- Breast Cancer
INZ-701 - ENPPI Deficiency
Our lead candidate, INZ-701, is in clinical development for the potential treatment of ENPP1 Deficiency and ABCC6 Deficiency, which are driven by low levels of inorganic pyrophosphate (PPi) andadenosine. Currently, there are no therapeutic options for patients suffering from ENPP1 Deficiency and ABCC6 Deficiency – two rare disorders. We are pioneering the development of effective therapies for these patients and their families.
NTO-1152 Clorestazine
Nanotherapeutics
SPN817
CNS-Seizures
CDX301
Various
VoyagerV-1
Cancer
Triapine™
Cancer
CDX3379
Cancer
ICON-1
AMD
CDX1401
Oncology
Radezolid
Antibacterial